Infinity Pharmaceuticals Inc. (NASDAQ:INFI) went down by -6.63% from its latest closing price compared to the recent 1-year high of $5.98. The company’s stock price has collected -13.60% of loss in the last five trading sessions. Press Release reported on 09/13/21 that Infinity to Participate in Oppenheimer’s Fall Healthcare Life Sciences and MedTech Summit and the 3(rd) Annual Macrophage-directed Therapies Summit
Is It Worth Investing in Infinity Pharmaceuticals Inc. (NASDAQ :INFI) Right Now?
Plus, the 36-month beta value for INFI is at 2.19. Opinions of the stock are interesting as 7 analysts out of 7 who provided ratings for Infinity Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $9.29. INFI currently public float of 86.79M and currently shorts hold a 6.96% ratio of that float. Today, the average trading volume of INFI was 7.47M shares.
INFI’s Market Performance
INFI stocks went down by -13.60% for the week, with a monthly jump of 4.52% and a quarterly performance of 0.00%, while its annual performance rate touched 202.80%. The volatility ratio for the week stands at 7.29% while the volatility levels for the past 30 days are set at 7.02% for Infinity Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is -4.99% for INFI stocks with a simple moving average of 6.52% for the last 200 days.
Analysts’ Opinion of INFI
Many brokerage firms have already submitted their reports for INFI stocks, with JP Morgan repeating the rating for INFI by listing it as a “Overweight.” The predicted price for INFI in the upcoming period, according to JP Morgan is $6 based on the research report published on August 02nd of the current year 2021.
Wells Fargo, on the other hand, stated in their research note that they expect to see INFI reach a price target of $14, previously predicting the price at $4. The rating they have provided for INFI stocks is “Overweight” according to the report published on July 28th, 2021.
B. Riley Securities gave a rating of “Buy” to INFI, setting the target price at $7 in the report published on July 07th of the current year.
INFI Trading at 8.83% from the 50-Day Moving Average
After a stumble in the market that brought INFI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.82% of loss for the given period.
Volatility was left at 7.02%, however, over the last 30 days, the volatility rate increased by 7.29%, as shares surge +3.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +13.29% upper at present.
During the last 5 trading sessions, INFI fell by -13.60%, which changed the moving average for the period of 200-days by +79.01% in comparison to the 20-day moving average, which settled at $3.42. In addition, Infinity Pharmaceuticals Inc. saw 52.83% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at INFI starting from BVF PARTNERS L P/IL, who sale 5,848,520 shares at the price of $4.14 back on Jan 22. After this action, BVF PARTNERS L P/IL now owns 686,974 shares of Infinity Pharmaceuticals Inc., valued at $24,205,855 using the latest closing price.
Stock Fundamentals for INFI
Current profitability levels for the company are sitting at:
- -2239.50 for the present operating margin
- +11.58 for the gross margin
The net margin for Infinity Pharmaceuticals Inc. stands at -2355.56. The total capital return value is set at -111.55, while invested capital returns managed to touch -120.32. Equity return is now at value -304.80, with -57.10 for asset returns.
When we switch over and look at the enterprise to sales, we see a ratio of 84.35, with the company’s debt to enterprise value settled at 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.26.